Breaking News Instant updates and real-time market news.

RUBY

Rubius Therapeutics

$9.93

1.08 (12.20%)

, HURN

Huron

$67.14

1.01 (1.53%)

08:12
11/04/19
11/04
08:12
11/04/19
08:12

Entrada Therapeutics appoints Nathan Dowden as COO

Entrada Therapeutics announced the appointment of Nathan J. Dowden as COO. Dowden was most recently Senior Vice President of Strategy and Corporate Development at Rubius (RUBY) Therapeutics and joins Entrada with almost 30 years of strategy, investment and operational experience in the healthcare field. While serving as Senior Vice President of Strategy and Corporate Development at Rubius, Dowden worked to develop and integrate the company's platform, capital formation and communication strategy to support the organization's evolution from an early discovery company into a clinical development organization. Prior to joining Rubius, Dowden served as Managing Director at the Huron Consulting Group (HURN).

RUBY

Rubius Therapeutics

$9.93

1.08 (12.20%)

HURN

Huron

$67.14

1.01 (1.53%)

  • 12

    Nov

  • 13

    Nov

RUBY Rubius Therapeutics
$9.93

1.08 (12.20%)

06/26/19
HCWC
06/26/19
INITIATION
Target $40
HCWC
Buy
Rubius Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated Rubius Therapeutics with a Buy rating and $40 price target, stating that he believes the company can generate Red Cell Therapeutics with "unprecedented efficiency." He thinks that Rubius' pipeline diversity and platform strength are underappreciated ahead of the first-in-human data for RTX-134 in phenylketonuria, which is due in the second half of the year.
07/11/19
HCWC
07/11/19
NO CHANGE
Target $40
HCWC
Buy
Rubius' RTX-240 offers differentiated value propositions, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein believes Rubius Therapeutics' RTX-240 offers differentiated value propositions that are being underappreciated by the market. The analyst has a bullish view on IL-15 in cancer treatment and RTX-240's "competitive strength" RTX-240 differentiates by presenting the natural conformation of IL-15/IL-15R-alpha, synergistic effects from 4-1BBL and improved safety profile with vascular bio-distribution, Fein tells investors in a research note. He keeps a Buy rating on Rubius Therapeutics with a $40 price target.
09/09/19
BARD
09/09/19
INITIATION
Target $4
BARD
Underperform
Rubius Therapeutics initiated with an Underperform at Baird
Baird started Rubius Therapeutics with an Underperform rating and $4 price target.
09/10/19
BARD
09/10/19
INITIATION
Target $4
BARD
Underperform
Rubius Therapeutics coverage initiated, dearth of data for platform says Baird
As reported previously, Baird analyst Madhu Kumar initiated coverage on Rubius Therapeutics with an Underperform rating as he believes there is a dearth of even preclinical data supporting its red cell therapeutic (RTC) platform particularly its lead asset RTX-134 which has an approved comparator drug and potentially disruptive gene therapy competition. Kumar has a $4 price target on Rubius Therapeutics shares.
HURN Huron
$67.14

1.01 (1.53%)

02/27/19
RHCO
02/27/19
NO CHANGE
Target $60
RHCO
Buy
Huron price target raised to $60 from $55 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Huron to $60 and kept his Buy rating, saying the company's education segment should benefit from the struggles of the universities business model. The analyst sees a "long-term runway for growth in the number and scope of engagements for Huron Education" after the segment registered a 16% organic revenue growth in 2018.
09/03/19
RHCO
09/03/19
NO CHANGE
Target $74
RHCO
Buy
Huron price target raised to $74 from $66 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Huron to $74 and kept his Buy raing, saying that after holding investor meetings with its management, his visibility on profitable growth for the company's Healthcare sector has improved. In a bull case scenario, the analyst claims that Huron can generate a 10% compound annual revenue growth through 2021 with EBITDA margin of 17%. Sommer adds that "significant catalysts" also exist for its Education business, with new student-focused tools for colleges and universities potentially leading to major large projects.
10/31/19
BRRR
10/31/19
NO CHANGE
Target $76
BRRR
Huron price target raised to $76 from $68 at Barrington
Barrington analyst Kevin Steinke maintained an Outperform rating on Huron and raised his price target on shares to $76 from $68 following Q3 earnings that exceeded expectations and FY19 guidance that was raised for the second time this year. The analyst said that Huron is "well-positioned for long-term organic growth" and sees "favorable long-term demand conditions across the business."

TODAY'S FREE FLY STORIES

INCY

Incyte

$92.79

-2.2 (-2.32%)

05:16
12/13/19
12/13
05:16
12/13/19
05:16
Recommendations
Incyte analyst commentary  »

Incyte risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

PCG

PG&E

$11.75

-0.38 (-3.13%)

05:14
12/13/19
12/13
05:14
12/13/19
05:14
Hot Stocks
PG&E files amended plan of reorganization »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

05:12
12/13/19
12/13
05:12
12/13/19
05:12
Recommendations
Sarepta price target raised to $210 from $185 at Piper Jaffray »

Piper Jaffray analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$11.81

-2.68 (-18.50%)

05:07
12/13/19
12/13
05:07
12/13/19
05:07
Downgrade
Lovesac rating change  »

Lovesac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

TDOC

Teladoc

$77.06

-0.36 (-0.46%)

05:04
12/13/19
12/13
05:04
12/13/19
05:04
Initiation
Teladoc initiated  »

Teladoc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTMI

TTM Technologies

$13.79

0.19 (1.40%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Upgrade
TTM Technologies rating change  »

TTM Technologies upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$34.41

0.41 (1.21%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Downgrade
Federated Investors rating change  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMK

AssetMark Financial

$27.31

0.42 (1.56%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
AssetMark Financial rating change  »

AssetMark Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCTR

Victory Capital

$21.68

0.235 (1.10%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Downgrade
Victory Capital rating change  »

Victory Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$47.08

0.395 (0.85%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
Eaton Vance rating change  »

Eaton Vance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$60.47

-0.37 (-0.61%)

04:59
12/13/19
12/13
04:59
12/13/19
04:59
Initiation
Papa John's initiated  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

NGLOY

Anglo American

$0.00

(0.00%)

04:57
12/13/19
12/13
04:57
12/13/19
04:57
Downgrade
Anglo American rating change  »

Anglo American assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
12/13/19
12/13
04:55
12/13/19
04:55
General news
Retail Sales less autos to be reported at 08:30 »

November Retail Sales…

04:55
12/13/19
12/13
04:55
12/13/19
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/13/19
12/13
04:55
12/13/19
04:55
General news
Breaking General news story  »

New York Federal Reserve…

ACB

Aurora Cannabis

$2.61

0.15 (6.10%)

, CRON

Cronos Group

$7.31

0.49 (7.18%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
MJBizDaily to hold a conference »

Marijuana Business…

ACB

Aurora Cannabis

$2.61

0.15 (6.10%)

CRON

Cronos Group

$7.31

0.49 (7.18%)

NFX

Newfield Exploration

$0.00

(0.00%)

CGC

Canopy Growth

$21.14

0.84 (4.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$287.22

3.3 (1.16%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
ASML management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

UBX

Unity Biotechnology

$8.30

0.61 (7.93%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Recommendations
Unity Biotechnology analyst commentary  »

Unity Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

COUP

Coupa Software

$136.91

-7.2 (-5.00%)

, CRWD

Crowdstrike

$47.25

-0.49 (-1.03%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
FBN to hold a bus tour »

17th Semi-Annual Silicon…

COUP

Coupa Software

$136.91

-7.2 (-5.00%)

CRWD

Crowdstrike

$47.25

-0.49 (-1.03%)

FEYE

FireEye

$16.33

0.095 (0.59%)

FSCT

ForeScout

$34.24

0.73 (2.18%)

FTNT

Fortinet

$104.45

0.29 (0.28%)

NOW

ServiceNow

$265.76

-1.665 (-0.62%)

NTAP

NetApp

$62.73

2.12 (3.50%)

PFPT

Proofpoint

$112.97

-0.03 (-0.03%)

PSTG

Pure Storage

$16.50

0.16 (0.98%)

QLYS

Qualys

$84.80

0.46 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 17

    Dec

  • 06

    Jan

  • 08

    Jan

  • 13

    Jan

  • 10

    Mar

  • 11

    Mar

  • 09

    Dec

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
BTIG biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

EA

Electronic Arts

$105.08

1.9 (1.84%)

, ATVI

Activision Blizzard

$58.60

2.12 (3.75%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

EA

Electronic Arts

$105.08

1.9 (1.84%)

ATVI

Activision Blizzard

$58.60

2.12 (3.75%)

GME

GameStop

$5.58

0.05 (0.90%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$125.33

2.95 (2.41%)

UBSFY

Ubisoft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

OGI

Organigram

$2.57

(0.00%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Organigram management to meet with Cantor Fitzgerald »

Analyst Pablo Zuanic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ABB

ABB

$23.62

0.685 (2.99%)

, MMM

3M

$168.54

-0.19 (-0.11%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Wolfe Research to hold a field trip »

European Multi-Industry…

ABB

ABB

$23.62

0.685 (2.99%)

MMM

3M

$168.54

-0.19 (-0.11%)

SCHN

Schnitzer Steel

$22.39

0.22 (0.99%)

UTX

United Technologies

$149.49

2.2 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

TTWO

Take-Two

$125.33

2.95 (2.41%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Take-Two management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

HY

Hyster-Yale Materials

$64.70

1.14 (1.79%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Hyster-Yale Materials management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.